<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We previously demonstrated high expression of primary-microRNA BIC (pri-miR-155) in Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) and lack of expression in most non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes including some Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cases </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, high expression of BIC was reported in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in comparison to pediatric <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:mpath ids='MPATH_458'>normal</z:mpath> peripheral-blood samples </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we extended our series of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases and cell lines to examine expression of BIC using <z:chebi fb="40" ids="33697">RNA</z:chebi> in situ hybridization (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ISH</z:e>) and quantitative RT-PCR (qRT-PCR) and of miR-155 using Northern blotting </plain></SENT>
<SENT sid="3" pm="."><plain>Both BIC <z:chebi fb="40" ids="33697">RNA</z:chebi> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ISH</z:e> and qRT-PCR revealed no or low levels of BIC in 25 BL tissue samples [including 7 Epstein-Barr virus (EBV)-positive cases] compared to <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="4" pm="."><plain>In agreement with these findings, no miR-155 was observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> tissues </plain></SENT>
<SENT sid="5" pm="."><plain>EBV-negative and EBV latency type I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines also showed very low BIC and miR-155 expression levels as compared to <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>Higher levels of BIC and miR-155 were detected in in vitro transformed lymphoblastoid EBV latency type III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines </plain></SENT>
<SENT sid="7" pm="."><plain>An association of latency type III <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and induction of BIC was supported by consistent expression of BIC in 11 and miR-155 in 2 posttransplantation <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> (PTLD) cases </plain></SENT>
<SENT sid="8" pm="."><plain>In summary, we demonstrated that expression of BIC and miR-155 is not a common finding in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Expression of BIC and miR-155 in 3 latency type III EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines and in <z:hpo ids='HP_0000001'>all</z:hpo> primary PTLD cases suggests a possible role for EBV latency type III specific proteins in the induction of BIC expression </plain></SENT>
</text></document>